Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Spyre Therapeutics, Inc. (SYRE) received a Rule 144 notice indicating that officer Heidy King-Jones plans to sell up to 46,665 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with sales planned beginning on or about 09/01/2026.
The shares were and will be acquired upon the exercise of stock options over the next three months, with the dates of acquisition and payment matching the exercise/sale dates. The filing lists an aggregate market value of approximately $4,168,584.45 for the shares and notes 88,173,762 shares outstanding as of 09/01/2026.
Spyre Therapeutics, Inc. (SYRE) reported topline data from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. In patients with moderate to severely active RA, SPY072 Low Dose achieved a statistically significant improvement in the primary endpoint, change from baseline in DAS28-CRP at Week 12 versus placebo. High and Low Dose arms also showed nominally significant advantages on key secondary and exploratory endpoints, including ACR20 and ACR50 response rates. SPY072 was well tolerated, with overall adverse event rates similar to placebo and no drug-related serious adverse events. The company stated that while the magnitude of effect did not meet its internal threshold to prioritize SPY072 as a monotherapy in RA, the data provide proof-of-mechanism for TL1A and support its potential in other autoimmune diseases and as a combination component. Spyre highlighted upcoming topline readouts across its I&I pipeline through 2027, including SPY003 in ulcerative colitis, additional SPY072 sub-studies in psoriatic arthritis and axial spondyloarthritis, and a combination study of SPY072 with IL-17A/F in hidradenitis suppurativa.
Spyre Therapeutics, Inc. has an institutional holder group led by Perceptive Advisors LLC reporting beneficial ownership of 4,319,496 shares of common stock. This represents 4.9% of the outstanding shares, based on 88,173,762 shares of common stock outstanding as of July 28, 2026.
The shares are held directly by Perceptive Life Sciences Master Fund, Ltd., while Perceptive Advisors LLC, as investment manager, and Joseph Edelman, as managing member of Perceptive Advisors, may be deemed to share voting and dispositive power over these shares. Each reporting person reports shared voting and dispositive power over 4,319,496 shares and no sole voting or dispositive power, and confirms ownership of 5 percent or less of this class.
Spyre Therapeutics, Inc. received an updated Schedule 13G/A (Amendment No. 2) reporting ownership by RTW Investments, LP and its managing partner and CIO, Roderick Wong, M.D. The reporting persons collectively report beneficial ownership of 4,251,996 shares of common stock, representing 4.8% of the class.
The shares are held by certain RTW-managed funds, with RTW Investments and Dr. Wong reporting shared voting and dispositive power over all 4,251,996 shares and no sole voting or dispositive power. The ownership percentage is based on 87,936,477 shares outstanding as of June 24, 2026 as reported by the company.
Spyre Therapeutics, Inc. director Jeffrey W. Albers reported an option exercise and related share sales on August 7, 2026. He exercised stock options covering 5,000 shares of common stock at a $10.39 exercise price and retained options on 45,000 shares. On the same date, he reported sales totaling 23,000 shares of common stock at weighted average prices slightly above $104 per share, including sales by Sessions LLC reported as indirect ownership. All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
Spyre Therapeutics, Inc. CFO Scott L. Burrows reported an option exercise-and-sale sequence on August 3, 2026. He exercised stock options for 7,500 shares of common stock at an exercise price of $14.50 per share, then sold 7,500 shares in three transactions at weighted average prices of $95.21, $96.30 and $97.10, all pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Following the transactions, he continues to hold options covering 344,857 shares that expire on September 1, 2033 and 67,476 restricted stock units vesting in two equal installments on September 1, 2026 and 2027, subject to continued employment.
Spyre Therapeutics, Inc. CEO Cameron Turtle sold a total of 15,000 shares of common stock on August 3, 2026 in five open-market transactions under a Rule 10b5-1 trading plan adopted on June 20, 2025, at weighted average prices between $93.97 and $97.46 per share.
The sales occurred across trade ranges from $93.42 to $97.47 per share. The reported holdings include 58,108 shares that vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics reported second quarter 2026 results and advanced its immunology pipeline. Positive topline Phase 2 induction data for SPY001 and SPY002 in ulcerative colitis showed statistically significant Robart’s Histopathology Index reductions of 9.2 and 10.7 points with robust clinical remission and endoscopic improvement rates and a safety profile consistent with in-class comparators.
The SKYWAY Phase 2 basket trial of anti-TL1A antibody SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis has completed enrollment, with proof-of-concept readouts expected from September through late 2026. Cash, cash equivalents and marketable securities were $1,145.3 million as of June 30, 2026, including $435.2 million in net proceeds from an April equity offering, supporting an expected cash runway into the second half of 2029. Net loss for the quarter was $36.2 million, as higher R&D spend of $65.5 million and G&A of $16.1 million were partially offset by a $40.0 million milestone gain on a legacy asset.